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The Talent endograft (Medtronic, Santa Rosa, Calif), which
has been available since 1995, is the abdominal aortic aneurysm
(AAA) endograft system that has been the longest sold under the
same name. In the past, a number of modifications have been
established to address problems of wire breaks. The changes in the
nitinol surface, the shape of the stent apexes, and the position of
the longitudinal bar were successful in enhancing metal fatigue
performance at bench testing and at radiographic follow-up assess-
ment in clinical studies.1,2 Not withstanding these improvements,
the basic design of the current Talent low profile system (LPS) is
identical to the previous generation.
The group of German collaborators, who have detailed their
experience with the Talent device during the first years of its
availability up to December 1998, are to be commended for their
effort. A mean follow-up period of 53 months after endovascular
aneurysm repair (EVAR) is not frequently reported, and for this
reason, this study may be of particular interest. A number of
weaknesses can be noted, however.
First, the study has a retrospective design, which inevitably
causes loss of important details. For instance, although the authors
reported the proportion of infrarenal necks that were wider or
shorter than recommended guidelines, other details such as neck
angulation or thrombus lining might have provided a more com-
plete picture. These omissions precluded assessment of the effect of
adverse anatomy on the long-term outcome of endovascular treat-
ment. The Talent endograft has been, during the many years of its
existence, the favorite choice of many interventionalists in patients
with more hostile anatomy. The device brand had the largest
available size range, and in addition, the option to order custom-
made devices for even more extreme conditions was available. A
long-term follow-up study as the present one should have provided
a comparison of the outcome in patients with complicated and
uncomplicated anatomic features.
Second, adverse events such as migration, endoleaks, and
secondary interventions were infrequent in this series. It appeared,
however, that these good results were at least partly due to consid-cently published study by EUROSTAR shows that the neck length
was15 mm in 16% vs 3.6%, and the aneurysm diameter was60
mm in 43% vs 23% in the EUROSTAR-Talent group and the
present series, respectively.3 These differences indicate the selec-
tion of relatively uncomplicated cases, whichmay explain the good,
long-term outcome in this series. It certainly would have been
interesting, when the authors had disclosed the proportion of
patients treated with a Talent endograft relative to all AAA-patients
treated during the study period.
Third, the indication of only the crude rates of device migra-
tion, endoleaks, and kinking or thrombosis of iliac device limbs was
another omission. In particular, when these events can be assessed
in a series with sufficiently long-term follow-up, assessment in
life-table format is indispensable. One would like to know whether
device migration or other problems occurred within the early
postoperative period or after a number of years. This knowledge is
essential for planning an effective and cost-conscious surveillance
schedule after EVAR.
Finally, considering the excellent long-term results obtained,
the authors might have touched upon the performance of the
current generation of stent-grafts, in particularly the Talent LPS
endograft, with a basically similar design after being in use for 10
years. Is this a device that needs to be replaced by a completely
redesigned stent-graft, or is it still up-to-date for the stent-graft
market in 2006? These are important questions, which still need to
be addressed in a future overview.
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